Caxton Associates LP Acquires New Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

Caxton Associates LP bought a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 59,625 shares of the company’s stock, valued at approximately $531,000.

A number of other institutional investors have also added to or reduced their stakes in VIR. Texas Permanent School Fund Corp increased its holdings in shares of Vir Biotechnology by 1.4% in the 1st quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company’s stock worth $760,000 after buying an additional 1,012 shares during the last quarter. Ballentine Partners LLC grew its position in Vir Biotechnology by 9.2% in the first quarter. Ballentine Partners LLC now owns 13,704 shares of the company’s stock worth $139,000 after acquiring an additional 1,160 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in Vir Biotechnology by 2.8% in the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock valued at $390,000 after acquiring an additional 1,200 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Vir Biotechnology by 20.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,186 shares of the company’s stock valued at $113,000 after purchasing an additional 1,869 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Vir Biotechnology by 249.9% during the first quarter. GAMMA Investing LLC now owns 2,708 shares of the company’s stock worth $27,000 after purchasing an additional 1,934 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on VIR. Barclays boosted their target price on Vir Biotechnology from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Needham & Company LLC lifted their price target on Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, June 5th. Morgan Stanley upped their price target on shares of Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Thursday, June 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $36.80.

Vir Biotechnology Trading Up 0.6 %

VIR opened at $7.30 on Friday. Vir Biotechnology, Inc. has a 12-month low of $7.20 and a 12-month high of $13.09. The company has a market cap of $997.47 million, a price-to-earnings ratio of -1.82 and a beta of 0.46. The stock has a fifty day simple moving average of $8.60 and a two-hundred day simple moving average of $9.29.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.13). Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The business had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $7.53 million. During the same period last year, the business earned ($1.45) earnings per share. The company’s revenue was down 19.0% on a year-over-year basis. On average, analysts predict that Vir Biotechnology, Inc. will post -3.26 EPS for the current year.

Insider Activity at Vir Biotechnology

In related news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the completion of the transaction, the director now directly owns 11,616 shares of the company’s stock, valued at approximately $90,604.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 15.60% of the stock is currently owned by corporate insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.